← Eichor
Study identifier: NCT07708116 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

First in Human Trial of CTX-187 in Healthy Volunteers and Chronically Infected Patients

Condition: Bronchiectasis Adult · Bronchiectasis With Pseudomonas Aeruginosa Colonization · Bacterial Infections  ·  Sponsor: Centauri Therapeutics Limited

PhasePhase 1
Planned participants104
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersYes

About this study

The primary objective of this trial is to assess the safety and tolerability of single and multiple ascending intravenously (IV) infused doses of CTX-187 when administered to healthy adult male and female participants and participants with a bacterial infection (bronchiectasis participants chronically infected with P. aeruginosa).

This description comes directly from the study's public registry record.

Talk to the study team

Centauri Clinical Team  ·  Please use email  ·  clinical@centauritherapeutics.com

Always discuss trial participation with your own doctor first.

Locations (1)

ICON Clinic, location GRQMGroningen, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07708116